This article was originally published in The Rose Sheet
Nexxus and Tresemme fueled a 9.2% increase in global consumer products sales to $360 mil. during the third quarter (ended June 30), and earnings before income taxes for the unit advanced 9.2% to $32.6 mil., Alberto announces July 27. The beauty supply business, which includes Sally Beauty and Beauty Systems Group, had sales of $599.5 mil., representing growth of 4%, while earnings before income taxes for the division were up 8.6% to $65.5 mil. Alberto's net sales in Q3 increased 6% to $952.7 mil. Due to a $50 mil. termination fee associated with the failed merger of Alberto's beauty supply business with Regis Corporation, Alberto's net earnings plummeted 42.9% to $30.5 mil., including non-core items. Alberto recently announced it will spin off Sally as a separate entity in a transaction expected to close in December (1"The Rose Sheet" June 26, 2006, p. 3)...
You may also be interested in...
Alberto-Culver's consumer products division will make acquisitions a top priority following the spin-off of Sally Beauty Company, the firm stated during a June 19 call announcing the decision
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.